Kringle Pharma and Maruho Agreed to Conclude an Option Agreement for ChronSeal®
- January 28, 2009
Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") proudly ann...
Home > News from Portfolio Companies > January 2009
January 2009
Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers
- January 28, 2009
Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") is proud to...
